RxDoctor Payments Data

Antonela Ratiu, APRN

Nurse Practitioner · Little River, SCNPI 1184008591

Payments from drug & device makers

$1,137in general payments, 2019–2025

Across 55 payments — averaging $20.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$277
  • AbbVie$178
  • Endo Pharmaceuticals Inc.$170
  • Medtronic$124
  • Ferring Pharmaceuticals Inc.$86
  • Coloplast$51
  • plus $251 from 10 others

What the payments were for

  • Food & beverage$1,137100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,137 in reported general payments places this provider in the 80th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$156,845
Medicare patients
977
Services billed
4,326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron62$58,647
MyrbetriqMirabegron45$29,713
Solifenacin Succinate182$10,224
Estradiol158$10,087
Tamsulosin Hcl583$9,204
Finasteride404$6,289
Alfuzosin Hcl ErAlfuzosin Hcl126$3,466
Testosterone17$1,803
Dutasteride21$1,269
Nystatin81$1,053
Oxybutynin Chloride47$1,015
Cephalexin263$934
Ciprofloxacin Hcl141$641
Testosterone Cypionate23$549
Mupirocin17$237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$277$58,64762 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in Little River

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →